Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.71 |
| ▸ | HPGD | P15428 | 2/20 | 0.71 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.71 |
| ▸ | MAPT | P10636 | 2/20 | 0.71 |
| ▸ | TSHR | P16473 | 1/20 | 0.71 |
| ▸ | LMNA | P02545 | 1/20 | 0.68 |
| ▸ | PKM | P14618 | 1/20 | 0.67 |
| ▸ | AKT1 | P31749 | 4/20 | 0.63 |
| ▸ | CA1 | P00915 | 3/20 | 0.62 |
| ▸ | CA2 | P00918 | 3/20 | 0.62 |
| ▸ | CA5A | P35218 | 2/20 | 0.62 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.62 |
| ▸ | CA12 | O43570 | 1/20 | 0.62 |
| ▸ | CA3 | P07451 | 1/20 | 0.62 |
| ▸ | CA6 | P23280 | 1/20 | 0.62 |
| ▸ | CA9 | Q16790 | 1/20 | 0.62 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.62 |
| ▸ | CA4 | P22748 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 4/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30978753 | 0.86 | MEN1 (0.75) | ALDH1A1HPGDHSD17B10MAPTTSHR | |
| SCHEMBL5404442 | 0.86 | ALDH1A1 (0.71) | ALDH1A1HPGDHSD17B10MAPTTSHR | |
| Glybuzole SCHEMBL34401 | 0.85 | ALDH1A1 (0.71) | ALDH1A1HPGDHSD17B10MAPTTSHR | |
| SCHEMBL30578971 | 0.83 | ALDH1A1 (1.00) | ALDH1A1HPGDHSD17B10MAPTTSHR | |
| Sulfamethizole SCHEMBL26453 | 0.81 | ALDH1A1 (1.00) | ALDH1A1HPGDLMNAPKMAKT1 | |
| SCHEMBL286763 | 0.80 | ALDH1A1 (1.00) | ALDH1A1HPGDHSD17B10MAPTTSHR | |
| Sulfamethizole SCHEMBL1566142 | 0.79 | ALDH1A1 (0.97) | ALDH1A1HPGDLMNAPKMAKT1 | |
| SCHEMBL5401782 | 0.79 | ALDH1A1 (0.65) | ALDH1A1HPGDHSD17B10MAPTTSHR | |
| Sulfamethizole SCHEMBL28693374 | 0.78 | ALDH1A1 (0.94) | ALDH1A1HPGDLMNAPKMAKT1 | |
| SCHEMBL328580 | 0.78 | LMNA (0.68) | ALDH1A1TSHRLMNAAKT1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1470 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021054927-A2 | GLUTATHIONE-CHOLESTEROL DERIVATIVES AS BRAIN TARGETING AGENTS | SOUTH DAKOTA BOARD OF REGENTS (US) | 2021-03-25 | — | — | WO | claimed |
| EP-2459227-B1 | Prodrugs containing an aromatic amine connected by an amide bond to a carrier | ASCENDIS PHARMA AS (DK) | 2021-03-17 | — | — | EP | claimed |
| US-20200048305-A1 | GLUTATHIONE-CHOLESTEROL DERIVATIVES AS BRAIN TARGETING AGENTS | SOUTH DAKOTA BOARD OF REGENTS (US) | 2020-02-13 | — | — | US | claimed |
| US-9622969-B2 | Polymer conjugated protein micelles | SOUTH DAKOTA STATE UNIV (US) | 2017-04-18 | — | — | US | claimed |
| US-9173953-B2 | Prodrugs containing an aromatic amine connected by an amido bond to a linker | ASCENDIS PHARMA AS (DK) | 2015-11-03 | — | — | US | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-20140370110-A1 | POLYMER CONJUGATED PROTEIN MICELLES | SOUTH DAKOTA STATE UNIVERSITY (US) | 2014-12-18 | — | — | US | claimed |
| US-20140296141-A1 | Compositions and Methods for Treating Obesity, Obesity Related Disorders and for Inhibiting the Infectivity of Human Immunodeficiency Virus | THE GENERAL HOSPITAL CORPORATION (US) | 2014-10-02 | — | — | US | claimed |
| US-8591947-B2 | Dual controlled release dosage form | Osmotica Kereskedelmi és Szolgáltató KFT (HU) | 2013-11-26 | — | — | US | claimed |
| US-20130108693-A1 | Dual Controlled Release Dosage Form | OSMOTICA KERESKEDELMI ES SZOLGALTATO KFT (HU) | 2013-05-02 | — | — | US | claimed |
| WO-2002015892-A2 | COMBINATION COMPRISING AN INSULIN SECRETION ENHANCER AND AN ACTIVE INGREDIENT SELECTED FROM HMG-CO-A REDUCTASE INHIBITORS AND ACE INHIBITORS | NOVARTIS AG (CH) | 2002-02-28 | — | — | WO | claimed |
| WO-2002015933-A2 | COMBINATION COMPRISING AN AT1-RECEPTOR ANTAGONIST AND AN INSULIN SECRETION ENHANCER OR AN INSULIN SENSITISER | NOVARTIS AG (CH) | 2002-02-28 | — | — | WO | claimed |
| US-6329404-B1 | Pharmaceutical composition | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-12-11 | — | — | US | claimed |
| US-6303640-B1 | ADMINISTERING OXAZOLE OR THIAZOLE DERIVATIVE COMPOUND FOR REDUCING SIDE EFFECTS OF DIABETIC THERAPY | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-10-16 | — | — | US | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| US-6211205-B1 | ANTIDIABETIC AGENTS THAT ENHANCE INSULIN SECRETION | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-04-03 | — | — | US | claimed |
| US-6150383-A | COMPRISING AN INSULIN SENSITIVITY ENHANCER IN COMBINATION WITH ONE OR MORE OTHER ANTIDIABETICS DIFFERING FROM THE ENHANCER IN MECHANISM OF ACTION; LIPID/GLYCOMETABOLISM DISORDERS; ANTIDIABETIC AGENTS; SIDE EFFECT REDUCTION | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2000-11-21 | — | — | US | claimed |
| EP-0007911-A4 | ZINC AND/OR CERIUM CONTAINING SULFONYLUREA HYPOGLYCEMIC AGENTS, PREPARATION AND USE THEREOF. | RESEARCH CORP (US) | 1981-02-25 | — | — | EP | claimed |
| EP-0007911-A1 | ZINC AND/OR CERIUM CONTAINING SULFONYLUREA HYPOGLYCEMIC AGENTS, PREPARATION AND USE THEREOF | Research Corporation (US) | 1980-02-06 | — | — | EP | claimed |
| WO-1979000435-A1 | ZINC AND/OR CERIUM CONTAINING SULFONYLUREA HYPOGLYCEMIC AGENTS,PREPARATION AND USE THEREOF | RESEARCH CORP (US) | 1979-07-12 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200048305-A1 | GLUTATHIONE-CHOLESTEROL DERIVATIVES AS BRAIN TARGETING AGENTS | GSTK1, GSTO1, GSTM2 | ALDH1A1 2491/4885HPGD 348/4885HSD17B10 492/4885 |
| US-20140370110-A1 | POLYMER CONJUGATED PROTEIN MICELLES | MTDH, PSMG3, GHITM | ALDH1A1 4150/4885HPGD 2962/4885HSD17B10 3318/4885 |
| US-20140296141-A1 | Compositions and Methods for Treating Obesity, Obesity Related Disorders and for Inhibiting the Infectivity of Human Immunodeficiency Virus | LPL, ADIPOR2, EBP | ALDH1A1 884/4885HPGD 1103/4885HSD17B10 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.